Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
CSL Behring Canada Inc.
Indication:
Hereditary Angioedema
Last updated June 25, 2026
Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
HIV-1 Infection
Last updated June 25, 2026
Status:
Concluded with an LOI
Manufacturer:
Cipher
Indication:
Acne Vulgaris
Last updated June 25, 2026
Name to be determined (ranibizumab)
Status:
Active negotiation
Manufacturer:
Sandoz Canada Inc.
Indication:
Neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy
Last updated June 17, 2026
Status:
Concluded without agreement
Manufacturer:
Janssen Inc.
Indication:
For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy.
Last updated June 16, 2026
Status:
Concluded without agreement
Manufacturer:
Biogen Canada Inc.
Indication:
Friedreich's ataxia
Last updated June 10, 2026
Elfabrio (pegunigalsidase alfa)
Status:
Active negotiation
Manufacturer:
Chiesi Canada Corporation
Indication:
Fabry Disease
Last updated June 9, 2026
Status:
Negotiations were not pursued
Manufacturer:
Arcutis Biotherapeutics, Inc.
Indication:
Atopic dermatitis
Last updated June 5, 2026
Status:
Negotiations were not pursued
Manufacturer:
Amgen Canada Inc.
Indication:
Thyroid Eye Disease
Last updated June 5, 2026
Status:
Active negotiation
Manufacturer:
Orimed Pharma
Indication:
psychotic disorders, mood disorders, and major depressive disorder
Last updated June 3, 2026